2 March 2021
BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that...